LLY · 10-Q · 2026Q3 · Full report

Liquidity and Cash Position

ELI LILLY & Co · 2026-10-29 · Importance 60 · Surprise 40 · Matches filing data

Cash and cash equivalents were $4.9 billion at September 30, 2026, down from $7.3 billion at December 31, 2025; total investments increased to $4.1 billion from $2.9 billion. Total debt was $49.5 billion at September 30, 2026, an increase of $7.0 billion from year-end 2025. Lilly had $10.1 billion of unused committed bank credit facilities, including $10.0 billion available to support its commercial paper program, and reported approximately $862 million in unfunded venture-capital commitments payable over up to 10 years.

Key facts

• Lilly's total debt was $49.5 billion at September 30, 2026, an increase of $7.0 billion from $42.5 billion at December 31, 2025. source
• Lilly issued $9.0 billion of long-term debt in May 2026 and used the net proceeds for general corporate purposes, including repaying commercial paper and funding part of the upfront consideration and related costs for the Centessa and Kelonia acquisitions. source
• At September 30, 2026, Lilly had $10.1 billion of unused committed bank credit facilities, of which $10.0 billion was available to support its commercial paper program. source
• At September 30, 2026, Lilly had approximately $862 million of unfunded commitments to invest in venture capital funds, anticipated to be paid over up to 10 years. source
• Lilly's cash and cash equivalents were $4.9 billion at September 30, 2026, compared with $7.3 billion at December 31, 2025. source
• Lilly held total investments of $4.1 billion at September 30, 2026, compared with $2.9 billion at December 31, 2025. source
• Lilly expects its available cash and cash equivalents, operating cash flow generation, and access to short- and long-term borrowings to be sufficient to fund existing and planned capital requirements. source

Impact estimates